500713 EphA Antagonist - Calbiochem

500713
View Pricing & Availability

Overview

Replacement Information

Key Specifications Table

Empirical Formula
C₁₃H₁₃NO₃

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
5.00713.0001
Retrieving availability...
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Glass bottle 10 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity needs to be mulitiple of
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA pyrrolyl benzoic acid that effectively competes against ephrin-B3 for EphA4 binding as well as against ephrin-A1/-A2/-A3/-A5 for EphA2 and EphA4 binding by targeting EphA2/A4 high affinity ephrin-binding pocket in a reversible manner, exhibiting much reduced or no potency against ephrin-A4 for EphA2/EphA4 binding, ephrin-A5 for EphA3/A5/A6/A7 binding, ephrin-B2 for B1/B2/B3/B4/B6 binding, or ephrin-B2 for EphA4 binding. Shown to inhibit ephrin-A1-induced EphA2 phosphorylation (by 92% at 200 µM) and ephrin-A5-induced EphA4 phosphorylation (by 79% at 400 µM) in cultures in vitro and prevent ephrin-A5-induced growth cone collapse of neurons in 6-d chicken embryo retina (by 100% at 400 µM) ex vivo, as well as rescue human mutant SOD-1 A4V transgene-induced axonopathy in zebrafish embryos (500 µM from 6 to 30 hpf) in vivo.
      Catalogue Number500713
      Brand Family Calbiochem®
      Synonyms4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxybenzoic acid, EphA2 Antagonist, EphA4 Antagoinst, Ephrin Receptor Antagonist, Rtk2 Antagonist, Rtk1 Antagonist
      References
      ReferencesVan Hoecke, A., et al. 2012. Nat. Med. 18, 1418.
      Noberini, R., et al. 2008. J. Biol. Chem. 283, 29461.
      Product Information
      FormOrange powder
      Hill FormulaC₁₃H₁₃NO₃
      Chemical formulaC₁₃H₁₃NO₃
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetEphA
      Primary Target IC<sub>50</sub>3 micro
      Purity≥95% by HPLC
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      EphA Antagonist - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      References

      Reference overview
      Van Hoecke, A., et al. 2012. Nat. Med. 18, 1418.
      Noberini, R., et al. 2008. J. Biol. Chem. 283, 29461.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision21-June-2013 JSW
      Synonyms4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxybenzoic acid, EphA2 Antagonist, EphA4 Antagoinst, Ephrin Receptor Antagonist, Rtk2 Antagonist, Rtk1 Antagonist
      DescriptionA pyrrolyl benzoic acid that effectively competes against ephrin-B3 for EphA4 binding as well as against ephrin-A1/-A2/-A3/-A5 for EphA2 and EphA4 binding by targeting EphA2/A4 high affinity ephrin-binding pocket in a reversible manner (Ki = 6-10 and 11-14 µM against ephrin-A5 binding to EphA4 and EphA2, respectively), exhibiting much reduced or no potency against ephrin-A4 for EphA2/EphA4 binding, ephrin-A5 for EphA3/A5/A6/A7 binding, ephrin-B2 for B1/B2/B3/B4/B6 binding, or ephrin-B2 for EphA4 binding. Shown to inhibit 0.1 µg/mL ephrin-A1-Fc fusion-induced EphA2 phosphorylation in COS7 (by 92% at 200 µM) and 0.5 µg/mL ephrin-A5-Fc fusion-induced EphA4 phosphorylation in HT22 neuronal cultures (by 42% and 79% respectively, at 300 and 400 µM) without any cytotoxicity (up to 400 µM and 3 days in HT22 cultures). Also effective toward chicken and zebrafish EphA4 orthologs as evidenced by its efficacy in preventing 1 µg/mL ephrin-A5-Fc-induced growth cone collapse of neurons in 6-d chicken embryo retina (by 100% at 400 µM) ex vivo and in fully rescuing human mutant SOD-1 A4V transgene-induced axonopathy in zebrafish embryos (500 µM; treatment period from 6 to 30 hpf) in vivo.
      FormOrange powder
      Intert gas (Yes/No) Packaged under inert gas
      Chemical formulaC₁₃H₁₃NO₃
      Structure formulaStructure formula
      Purity≥95% by HPLC
      SolubilityDMSO (100 mg/ml)
      Storage +2°C to +8°C
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesVan Hoecke, A., et al. 2012. Nat. Med. 18, 1418.
      Noberini, R., et al. 2008. J. Biol. Chem. 283, 29461.